Fundraising Fox
Epiliquid
Founded 2021 · 9 employees on LinkedIn · 2 known investors
Find your way into Epiliquid
Sign up to see every warm intro you have to Epiliquid
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Epiliquid team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Epiliquid develops blood-based molecular tests for cancer detection and differential diagnosis using a platform that combines AI-driven methylation biomarker discovery, patented native-DNA assay chemistry, and PCR-based readout. Its technology measures multiple methylation biomarkers in a single PCR reaction and runs on the qPCR and digital PCR instruments clinical laboratories already use, serving precision oncology.
Investors · 2
Founder mafia
2 people who came through Epiliquid went on to found or lead other companies.
Frequently asked questions
- What does Epiliquid do?
- Epiliquid develops blood-based molecular tests for cancer detection and differential diagnosis using a platform that combines AI-driven methylation biomarker discovery, patented native-DNA assay chemistry, and PCR-based readout. Its technology measures multiple methylation biomarkers in a single PCR reaction and runs on the qPCR and digital PCR instruments clinical laboratories already use, serving precision oncology.
- Who are Epiliquid's investors?
- Epiliquid's investors include AIR Capital, CITES.